Enzo Biochem 4Q Loss Widens On Costs

NEW YORK (AP) ¿ Biotechnology company Enzo Biochem Inc. said Wednesday its fiscal fourth-quarter loss widened on a rise in general and administrative costs.

For the three months ended July 31, the company lost $5.3 million, or 14 cents per share, compared with a loss of $3.3 million, or 9 cents per share, a year ago. Revenue rose 16 percent to $24.5 million from $21.2 million.

The company provides diagnostic services and makes research products and medical tools.

Enzo said higher selling, general and administrative expenses amounted to 48 percent of net operating revenues, compared with 42 percent a year ago. The higher expenses were due in part to costs from the Assay Designs acquisition, accounting reviews and a provision for uncollectable accounts receivable, the company said.

For the full year, the company said it lost $23.6 million, or 63 cents per share, compared with a loss of $10.7 million, or 29 cents per share, a year prior. Revenue rose 15 percent to $89.6 million from $77.8 million.

Enzo shares rose 31 cents to close at $7.66 in the regular session. After hours, when the earnings report was issued, the stock fell 41 cents, or 5.4 percent, to $7.25.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Technology

10 Questions for PayPal Ahead of Its Big Investor Day

10 Questions for PayPal Ahead of Its Big Investor Day

High-Flying Mutual Funds Begin to Favor Energy but Tech Still Reigns Supreme

High-Flying Mutual Funds Begin to Favor Energy but Tech Still Reigns Supreme

EU Apple Users Can Now Download All the Info It Has on Them

EU Apple Users Can Now Download All the Info It Has on Them

Did Trump Just Torpedo the Stock Market Again?

Did Trump Just Torpedo the Stock Market Again?

Venture Capital Funding Surges 49% as Tech Innovation Piques Investor Interest

Venture Capital Funding Surges 49% as Tech Innovation Piques Investor Interest